ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Neobe Therapeutics, a London-based provider of a programmable bacterial therapeutics platform, raised $6.8M (£5M) in seed funding led by ARC Ventures. The round brought total capital to over $10.5M (£7.9M) for advancing its lead program NEO22 toward an IND filing in 2028.
Tap to vote and see what everyone thinks.
Summary by ByteBrief